{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:43:10Z","timestamp":1793515390993,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"BP \u2013 A Beneficencia Portuguesa de Sao Paulo"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.critrevonc.2019.06.012","type":"journal-article","created":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T10:42:22Z","timestamp":1562409742000},"page":"163-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1538-1929","authenticated-orcid":false,"given":"Viviane C.","family":"Ruiz-Schutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa M.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3641-0370","authenticated-orcid":false,"given":"Rodrigo C.","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-5049","authenticated-orcid":false,"given":"Daniel V.P.","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana M.","family":"Pimenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-0066","authenticated-orcid":false,"given":"Graziela Z.","family":"Dal Molin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio R.","family":"Kater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosely","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson F.","family":"Correa Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Maluf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio A.","family":"Schutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2019.06.012_bib0005","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/annonc\/mdw099","article-title":"Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors","volume":"27","author":"Abrahams","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0140-6736(03)14186-4","article-title":"Assessment and management of cancer-related fatigue in adults","volume":"362","author":"Ahlberg","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0015","author":"Astra-Zeneca"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0020","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.60.0320","article-title":"Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer","volume":"33","author":"Bang","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0025","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0030","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0035","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0040","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0045","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","article-title":"Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition","volume":"5","author":"Curt","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2016.10.010","article-title":"PARP inhibitor combination therapy","volume":"108","author":"Drean","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0060","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0065","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/ajco.12636","article-title":"Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer","volume":"12","author":"Friedlander","year":"2016","journal-title":"Asia. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0075","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","article-title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","volume":"19","author":"Friedlander","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0080","article-title":"Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group)","author":"Garcia-Campelo","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0085","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0090","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0100","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0105","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0110","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian Cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0115","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/14737140.2017.1355242","article-title":"Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis","volume":"17","author":"Lasheen","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0120","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0125","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5550","article-title":"Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)","author":"Matulonis","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0130","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0140","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0150","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0155","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0160","series-title":"Greenland S. Modern Epidemiology","author":"Rothman","year":"1998"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2019.06.012_bib0165","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1634\/theoncologist.12-S1-22","article-title":"Mechanisms of cancer-related fatigue","volume":"12","author":"Ryan","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.28715","article-title":"Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials","volume":"136","author":"Santoni","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0175","series-title":"Meta: an R Package for Meta-analysis, R News, 7(3), 40-45. R Core Team","author":"Schwarzer","year":"2017"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.critrevonc.2018.08.011","article-title":"The Era of PARP inhibitors in ovarian cancer: \"Class Action\" or not? A systematic review and meta-analysis","volume":"131","author":"Staropoli","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0185","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.molcel.2015.07.019","article-title":"PARP1- and CTCF-Mediated interactions between active and repressed chromatin at the Lamina promote oscillating transcription","volume":"59","author":"Zhao","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2019.06.012_bib0190","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2147\/DDDT.S147726","article-title":"Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials","volume":"11","author":"Zhou","year":"2017","journal-title":"Drug Des. Devel. Ther."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818305195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818305195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:33:53Z","timestamp":1760902433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818305195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":38,"alternative-id":["S1040842818305195"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.06.012","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}